This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pandha, H. S. Articles by Lemoine, N. R. Search for Related Content PubMed PubMed Citation Articles by Pandha, H. S. Articles by Lemoine, N. R. Social Bookmarking                            What's this?

Genetic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial of erbB-2–Directed Suicide Gene Expression

From the Imperial Cancer Research Fund Molecular Oncology Unit and Departments of Cancer Medicine and Histopathology, Imperial College School of Medicine, Hammersmith Campus, London, United Kingdom.

Address reprint requests to Nicholas R. Lemoine, MD, Imperial Cancer Research Fund Molecular Oncology Unit, Imperial College School of Medicine, Hammersmith Campus, London W12 0NN, United Kingdom; email: n.lemoine{at}icrf.icnet.uk

PURPOSE: This trial was designed to test the safety and efficacy of a tumor-specific genetic prodrug activation therapy targeted by use of the human erbB-2 gene promoter. The erbB-2 oncogene is overexpressed in approximately 20% of cases of breast cancer and is associated with poor prognosis.

PATIENTS AND METHODS: Twelve breast cancer patients received transcriptionally targeted gene therapy in a phase I clinical trial using direct intratumoral injection of plasmid construct combined with systemic administration of prodrug. The genetic prodrug activation therapy is specifically targeted to erbB-2–overexpressing breast cancer cells by use of a therapeutic cassette that contains the Escherichia coli cytosine deaminase gene driven by the tumor-specific erbB-2 promoter, thus allowing activation of fluorocytosine to the active cytotoxic fluorouracil only within tumor cells that express the oncogene.

RESULTS: The approach was shown to be safe and to result in targeted gene expression in up to 90% of cases. Using a number of different assays, we demonstrated that significant levels of expression of the suicide gene were specifically restricted to erbB-2–positive tumor cells, confirming the selectivity of the approach.

CONCLUSION: The results of this study, the first targeted gene therapy for breast cancer and the first to use the cytosine deaminase system in human subjects, are encouraging for the development of genetic prodrug activation therapies that exploit the transcriptional profile of cancer cells.

The contribution of each author is considered equal.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. P.F. Gade, J. A. Koutcher, W. M. Spees, B. J. Beattie, V. Ponomarev, M. Doubrovin, I. M. Buchanan, T. Beresten, K. L. Zakian, H. C. Le, et al. Imaging Transgene Activity In vivo Cancer Res., April 15, 2008; 68(8): 2878 - 2884. [Abstract] [Full Text] [PDF]

				M. L. Ramnaraine, W. E. Mathews, J. M. Donohue, C. M. Lynch, M. J. Goblirsch, and D. R. Clohisy Osteoclasts Direct Bystander Killing of Bone Cancer. Cancer Res., November 15, 2006; 66(22): 10929 - 10935. [Abstract] [Full Text] [PDF]

				M. Goblirsch, P. Zwolak, M. L. Ramnaraine, W. Pan, C. Lynch, P. Alaei, and D. R. Clohisy Novel Cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture. Clin. Cancer Res., May 15, 2006; 12(10): 3168 - 3176. [Abstract] [Full Text] [PDF]

				F. Ou-Yang, K.-L. Lan, C.-T. Chen, J.-C. Liu, C.-L. Weng, C.-K. Chou, X. Xie, J.-Y. Hung, Y. Wei, G. N. Hortobagyi, et al. Endostatin-Cytosine Deaminase Fusion Protein Suppresses Tumor Growth by Targeting Neovascular Endothelial Cells Cancer Res., January 1, 2006; 66(1): 378 - 384. [Abstract] [Full Text] [PDF]

				X. Li, J. Zhang, H. Gao, E. Vieth, K.-H. Bae, Y.-P. Zhang, S.-J. Lee, S. Raikwar, T. A. Gardner, G. D. Hutchins, et al. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by {alpha}-lactalbumin promoter Mol. Cancer Ther., December 1, 2005; 4(12): 1850 - 1859. [Abstract] [Full Text] [PDF]

				S. Li, B. Yu, P. An, G. Chen, W. Lu, H. Cai, W. Guo, and F. Zuo Combined Liposome-Mediated Cytosine Deaminase Gene Therapy with Radiation in Killing Rectal Cancer Cells and Xenografts in Athymic Mice Clin. Cancer Res., May 1, 2005; 11(9): 3574 - 3578. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				M. Schuldiner, J. Itskovitz-Eldor, and N. Benvenisty Selective Ablation of Human Embryonic Stem Cells Expressing a "Suicide" Gene Stem Cells, May 1, 2003; 21(3): 257 - 265. [Abstract] [Full Text] [PDF]

				A. Rosner, K. Miyoshi, E. Landesman-Bollag, X. Xu, D. C. Seldin, A. R. Moser, C. L. MacLeod, G. Shyamala, A. E. Gillgrass, and R. D. Cardiff Pathway Pathology : Histological Differences Between ErbB/Ras and Wnt Pathway Transgenic Mammary Tumors Am. J. Pathol., September 1, 2002; 161(3): 1087 - 1097. [Abstract] [Full Text] [PDF]

				G. Xu and H. L. McLeod Strategies for Enzyme/Prodrug Cancer Therapy Clin. Cancer Res., November 1, 2001; 7(11): 3314 - 3324. [Abstract] [Full Text] [PDF]

				L. Ermert, A. C. Hocke, H.-R. Duncker, W. Seeger, and M. Ermert Comparison of Different Detection Methods in Quantitative Microdensitometry Am. J. Pathol., February 1, 2001; 158(2): 407 - 417. [Abstract] [Full Text] [PDF]